Table 3.
Treatment patterns and costs during observation period
| Treatment pattern | BAK-free travoprost | Bimatoprost | Latanoprost |
|---|---|---|---|
| Number remaining on index therapy (n) | 203 | 747 | 1651 |
| Remained on monotherapy (%)** | 65.0% | 48.7% | 62.8% |
| Required adjunctive therapy (%)** | 35.0% | 51.3% | 37.3% |
| Median time to adding adjunctive therapy (days) | 113 | 83 | 101 |
| Mean time to adding adjunctive therapy (days); mean ± SD (interquartile range)** | 221 ± 223 (56–397) | 140 ± 156 (34–175) | 181 ± 187 (41–263) |
| Type of adjunctive therapy | |||
| α2-adrenergic receptor agonist (%) | 19.7% | 26.1% | 24.6% |
| Beta-blocker (%) | 35.2% | 24.5% | 34.1% |
| Carbonic anhydrase inhibitor (%) | 7.0% | 7.0% | 5.4% |
| Fixed-combination beta-blocker- carbonic anhydrase-inhibitor (%) | 28.2% | 35.2% | 29.4% |
| Other adjunctive therapy (%) | 9.9% | 7.0% | 6.5% |
| Number of prescriptions of index prostaglandin | 10.7 ± 6.2 | 13.5 ± 7.6 | 13.6 ± 9.5 |
| Total costs, 24 months | $2556.87 | $3147.40 | $2842.60 |
**
Note: P < 0.0001 across treatment groups.
Abbreviations: BAK, benzalkonium chloride; SD, standard deviation.